Über 20. Mio. Aktien gehandelt
282 Meter Gold im ersten Loch – Neue Bohrdaten stärken das Quinchía-System
Anzeige

EQS-News: Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases 25.10.2022, 10:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Proteros biostructures GmbH / Key word(s): Alliance
Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

25.10.2022 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases
 

  • Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engine
  • Proteros to support Adrestia in the discovery of first-in-class drugs for intractable genetic diseases
  • Signals new phase for Adrestia’s portfolio of validated synthetic rescue targets moving into drug discovery for genetically defined neurologic and cardiomyopathic diseases

 Martinsried/Munich, Germany – October 25, 2022 – Proteros biostructures GmbH (“Proteros”) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases. Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the company’s experienced discovery teams.

The partnership brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with Adrestia’s expertise in target biology with a novel synthetic rescue drug development platform. The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases. The partnership is already providing Adrestia with world-first protein crystal structures and is using both the Swiss Light Source (Villigen, Switzerland) and the Diamond Light Source, the UK's synchrotron facility, to enable rapid drug design.

“Adrestia’s carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros. We are delighted to support Adrestia in their accelerated drug discovery endeavors for a variety of complex targets to treat genetic diseases,” said Dr. Debora Konz Makino, Proteros’ VP Business Unit Discovery Solutions.

“Given our high conviction in our novel targets, we are applying parallel drug discovery strategies to maximize probability of success and accelerate timelines to IND. I’m thrilled to be working with Proteros,” said Dr. Tom Heightman, Adrestia’s Chief Research and Development Officer.

About Proteros biostructures GmbH

Proteros is a privately-held company with expertise in structure-based drug discovery powered by a cutting-edge discovery engine tailored to unlock even the most technically challenging disease-relevant targets. The company provides small molecule drug discovery services and its comprehensive enabling technology platforms, coupled with roots to Nobel Prize winning science and the Max Planck Institute of Biochemistry, have enabled prominent contributions to several lead optimization programs and clinical-stage compounds.

Proteros’ scientific rigor can accelerate overall research timelines for clients by solving the “High-hanging-fruits” of the early drug discovery and development stages and the company is consistently seen as the go-to partner for Hit to Lead Optimisation services. Proteros supports many of the world’s top 20 largest pharmaceutical companies and more than 200 pharmaceutical and biotech partners in the U.S., Europe and Japan.

For more information please visit www.proteros.com.

About Adrestia

Adrestia is a leader in synthetic rescue therapies for genetic diseases. As many directly causative mutations are not druggable, synthetic rescue embraces the much broader target set represented by functionally connected genes, to correct the effects of the causative mutations and ‘rescue’ health. Adrestia is creating a synthetic rescue ‘Atlas’ of the human genome and advancing a portfolio of first-in-class therapies, initially for neurologic, neuromuscular and cardiomyopathic diseases. Adrestia’s platform and in-house programs are complemented by a target discovery alliance with GSK and a Huntington’s disease collaboration with noted researchers including Dr Sarah Tabrizi at University College London.

Adrestia was co-founded by Professor Steve Jackson and the deep technology investment fund Ahren Innovation Capital, which co-led Adrestia’s Series A financing along with GSK. Jackson co-originated the first synthetic lethality drug, olaparib, which was the first drug approved to treat cancers caused by inherited mutations. For further information, visit: www.adrestia.com.

Contact Information

For Proteros

Dr. Debora Konz Makino
VP Business Unit Discovery Solutions   
Phone: +49 89 700761-0
Email: info@proteros.com

Media Contacts
Shaun Brown
Executive Director
MC Services AG
Phone: +44 7867 515 918
Email: shaun.brown@mc-services.eu


For Adrestia
Investors
Robert Johnson
investors@adrestia.com

Media
Tom Donovan
tom@lyrebird.bio
+1 857 559 3397



25.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1470793  25.10.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1470793&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer